Nbryo Pty Ltd completes AUD $10 Million Capital Raising to Accelerate Genetic Improvement in Beef & Dairy

The round was co-led by existing investor Tenacious Ventures and joined by new investor New Zealand–based AgriZeroNZ. Queensland Investment Corporation (QIC) also joined as a new investor. In addition, the founding Murdoch family contributed further funding together with existing private shareholders including ongoing support from Mandalay Venture Partners.

This raise also triggered the conversion of $12.3 million of the SAFE notes bringing the total to more than $22m raised since 2024. Nbryo, along with it’s research partners, has also received over $18 million grant funding for research and development from the Gates Foundation, Meat and Livestock Australia and other state and federal programs.

“We are grateful for the continued confidence shown by our investors, and supporters” said Paul Niven, CEO of Nbryo Pty Ltd. “This capital raising provides the resources we need to accelerate delivery of our technology platform and expand our impact in livestock reproduction. globably”

With this new funding, Nbryo will:

• Further accelerate our technology delivery, with an increased focus on advancing its proprietary IVF platform.
• Further expand our commercial IVF and Embryo Transfer (ET) services in the Australian cattle industry. 
• Launch embryo multiplication technology in late 2025, opening new opportunities for efficiency and herd improvement.
• Continue development of its world leading embryo transfer device, which is on track for market release in October 2026.

This strategic investment underscores the growing recognition of Nbryo’s potential to reshape cattle reproduction globally and deliver solutions at the intersection of biotechnology and digital agriculture. Nbryo-powered genetic gain will deliver operating e iciencies and sustainability-linked outcomes at a pace that cannot be achieved with conventional genetic improvement programs.